Will Cytokines Alter the Treatment of Myelodysplasic Syndrome?
- 1 February 1993
- journal article
- review article
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 305 (2) , 72-78
- https://doi.org/10.1097/00000441-199302000-00002
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromesBritish Journal of Haematology, 1991
- The myelodysplastic syndromes: biology and implications for management.Journal of Clinical Oncology, 1990
- Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromesBlood, 1990
- Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factorThe International Journal of Cell Cloning, 1990
- Granulocyte-Macrophage Colony-Stimulating Factor: Pleiotropic Cytokine with Potential Clinical UsefulnessClinical Infectious Diseases, 1990
- Circulating erythropoietin in patients with myelodysplastic syndromesBritish Journal of Haematology, 1989
- Treatment of Myelodysplastic Syndromes with Recombinant Human Granulocyte Colony-Stimulating FactorAnnals of Internal Medicine, 1989
- Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary reportThe American Journal of Medicine, 1989
- Phase I/II study of recombinant human granulocyte-macrophage colony- stimulating factor in aplastic anemia and myelodysplastic syndromeBlood, 1988
- Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic SyndromesNew England Journal of Medicine, 1987